The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adjuvant chemotherapy for HER2-positive early breast cancer patients without perioperative radiotherapy in trastuzumab era.
 
Kazuki Nozawa
No Relationships to Disclose
 
Keiji Sugiyama
No Relationships to Disclose
 
Kazuhiro Shiraishi
No Relationships to Disclose
 
Yoriko Funahashi
No Relationships to Disclose
 
Yoshihito Kogure
Honoraria - AstraZeneca; Chugai Pharma; Lilly Japan; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca Japan; Lilly Japan
 
Tomonori Kawasaki
No Relationships to Disclose
 
Aya Kato
No Relationships to Disclose
 
Chiyoe Kitagawa
No Relationships to Disclose
 
Takako Hayashi
No Relationships to Disclose
 
Takako Morita
No Relationships to Disclose
 
Shu Ichihara
No Relationships to Disclose
 
Hideo Saka
Honoraria - AMCo; AstraZeneca Japan; Becton Dickinson; Boehringer Ingelheim; Boston Scientific; Chugai Pharma; Covidien; Kirin Pharmaceuticals; Lilly Japan; MSD; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca Japan (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Lilly Japan (Inst); MSD (Inst); Novartis (Inst); Olympus (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Quintiles (Inst); Takeda (Inst)
 
Yasuyuki Sato
No Relationships to Disclose